EUVIMED · CrossrefJournal
Blood Cancer Journal
ISSN 2044-5385 · Springer Science and Business Media LLC
Latest articles
Impact of race/ethnicity, donor and recipient age, and donor on survival after allogeneic transplant in the post-transplant cyclophosphamide era
Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)
Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS
Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma
Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies
Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
CAPA induction followed by sequential radiotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma: a multicentre, single-arm, phase 2 trial
Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction
Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma
Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R
Socioeconomic deprivation does not affect survival outcomes in patients with mantle cell lymphoma: evidence from a German nationwide study
Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma
Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma
Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
Persistence of M-proteins detected by mass spectrometry
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia
Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia
Patterns and perceptions of supplement use among patients with plasma cell disorders
Infectious complications following bispecific antibody or CAR T therapy in adult patients with hematologic malignancies: a retrospective database analysis
Dynamics of in vivo immune remodeling in Ph+ all patients receiving frontline ponatinib and blinatumomab therapy
Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity
Hair bulb and oral mucosa DNA for prompt germline testing in hematologic neoplasms
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
Bosmolisib (BR101801), a novel PI3K-δ/γ and DNA-PK inhibitor for relapsed/refractory patients with peripheral T-cell lymphoma: a phase I study
Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study
EUVIMED